Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yulia Volovik

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|September 11, 2009
Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailabilityYulia Volovik Frenkel, Emilio Gallicchio, Kalyan Das, et al.
Nature Structural Biology|February 28, 2002
Structural basis of BLyS receptor recognitionDeena A Oren, Yuling Li, Yulia Volovik, et al.
Journal of Medicinal Chemistry|March 18, 2005
Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailabilityYulia Volovik Frenkel, Arthur D Clark, Kalyan Das, et al.
Drugs in R&D|September 11, 2004
Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compoundsPaul Lewi, Eddy Arnold, Koen Andries, et al.
Journal of Medicinal Chemistry|March 18, 2005
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)Paul A J Janssen, Paul J Lewi, Eddy Arnold, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|September 11, 2009
Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailabilityYulia Volovik Frenkel, Emilio Gallicchio, Kalyan Das, et al.
Nature Structural Biology|February 28, 2002
Structural basis of BLyS receptor recognitionDeena A Oren, Yuling Li, Yulia Volovik, et al.
Journal of Medicinal Chemistry|March 18, 2005
Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailabilityYulia Volovik Frenkel, Arthur D Clark, Kalyan Das, et al.
Drugs in R&D|September 11, 2004
Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compoundsPaul Lewi, Eddy Arnold, Koen Andries, et al.
Journal of Medicinal Chemistry|March 18, 2005
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)Paul A J Janssen, Paul J Lewi, Eddy Arnold, et al.
Pageof 1